Applied Therapeutics to Present at 2024 RBC Healthcare Conference

NEW YORK, May 7, 2024 — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical firm, will be partaking in a fireside chat during the 2024 RBC Capital Markets Global Healthcare Conference. This event is scheduled for Tuesday, May 14, 2024, at 4:35 p.m. ET in New York City. An accessible live webcast of the discussion can be found on the Events page within the Investor Relations section of the Applied Therapeutics website. A replay of the webcast will remain available on the company's site for 90 days following the event.

Applied Therapeutics is focused on developing innovative drug candidates targeting validated molecular markers for high unmet medical conditions. The company’s foremost drug candidate, govorestat, is an Aldose Reductase Inhibitor (ARI) capable of penetrating the central nervous system. It is being developed for the treatment of rare metabolic diseases such as Galactosemia, SORD Deficiency, and PMM2-CDG. Additionally, the company is working on AT-001, another potent ARI designed for treating Diabetic Cardiomyopathy (DbCM), a severe heart fibrosis condition. Their preclinical pipeline includes AT-003, an ARI intended for oral administration to treat Diabetic retinopathy by crossing into the back of the eye.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!